A detailed history of Great West Life Assurance CO transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 140,939 shares of CPRX stock, worth $3.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
140,939
Previous 147,245 4.28%
Holding current value
$3.37 Million
Previous $2.35 Million 6.99%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$14.68 - $16.92 $92,572 - $106,697
-6,306 Reduced 4.28%
140,939 $2.18 Million
Q1 2024

May 13, 2024

BUY
$13.18 - $17.11 $218,774 - $284,008
16,599 Added 12.71%
147,245 $2.35 Million
Q4 2023

Feb 13, 2024

SELL
$11.78 - $17.29 $99,988 - $146,757
-8,488 Reduced 6.1%
130,646 $2.19 Million
Q3 2023

Nov 14, 2023

BUY
$11.69 - $15.02 $97,588 - $125,386
8,348 Added 6.38%
139,134 $1.62 Million
Q2 2023

Aug 10, 2023

SELL
$11.5 - $18.08 $49,760 - $78,232
-4,327 Reduced 3.2%
130,786 $1.76 Million
Q1 2023

May 12, 2023

SELL
$14.34 - $21.05 $136,674 - $200,627
-9,531 Reduced 6.59%
135,113 $2.24 Million
Q4 2022

Feb 10, 2023

BUY
$12.25 - $19.5 $265,469 - $422,584
21,671 Added 17.62%
144,644 $2.7 Million
Q3 2022

Nov 01, 2022

BUY
$7.06 - $15.52 $868,189 - $1.91 Million
122,973 New
122,973 $1.58 Million
Q3 2020

Nov 17, 2020

BUY
$2.97 - $5.08 $8,595 - $14,701
2,894 Added 114.3%
5,426 $16,000
Q3 2020

Nov 13, 2020

SELL
$2.97 - $5.08 $8,595 - $14,701
-2,894 Reduced 53.34%
2,532 $7,000
Q4 2019

Feb 11, 2020

BUY
$3.67 - $5.7 $19,913 - $30,928
5,426 New
5,426 $20,000
Q3 2019

Oct 25, 2019

SELL
$3.89 - $7.43 $39,783 - $75,986
-10,227 Closed
0 $0
Q2 2019

Jul 31, 2019

BUY
$2.7 - $6.11 $27,612 - $62,486
10,227 New
10,227 $0

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.46B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.